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Abstract: The growing incidence of cardiovascular disease (CVD) has promoted investigations of
natural molecules that could prevent and treat CVD. Among these, hydroxytyrosol, a polyphenolic
compound of olive oil, is well known for its antioxidant, anti-inflammatory, and anti-atherogenic
effects. Its strong antioxidant properties are due to the scavenging of radicals and the stimulation of
synthesis and activity of antioxidant enzymes (SOD, CAT, HO-1, NOS, COX-2, GSH), which also limit
the lipid peroxidation of low-density lipoprotein (LDL) cholesterol, a hallmark of atherosclerosis.
Lowered inflammation and oxidative stress and an improved lipid profile were also demonstrated in
healthy subjects as well as in metabolic syndrome patients after hydroxytyrosol (HT) supplementation.
These results might open a new therapeutic scenario through personalized supplementation of HT in
CVDs. This review is the first attempt to collect together scientific literature on HT in both in vitro
and in vivo models, as well as in human clinical studies, describing its potential biological effects for
cardiovascular health.
Keywords: hydroxytyrosol; cardiovascular disease; atherosclerosis; oxidative stress; inflammation;
Mediterranean diet
1. Introduction
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the first
cause of death globally and have also led to an elevated economic impact. CVDs comprise several
disorders, such as heart failure, hypertension, coronary artery disease, peripheral vascular disease,
congenital heart disease, and stroke [1,2]. Lack of exercise, overweight and obesity, diabetes, stress,
alcohol consumption, aging, smoking habits, and unhealthy dietary patterns are all responsible for
increased CVD risk [3–5]. A large number of studies have clearly established that the Mediterranean
(Med) diet is the cornerstone of CVD prevention. In Med diet, virgin olive oil (VOO) and extra-virgin
olive oil (EVOO) are the major sources of fat and active phenolic compounds, responsible for
the minor mortality and morbidity noted in people on such a diet [1,6,7]. Besides high levels
of monounsaturated fatty acids (MUFA), VOO and mostly EVOO contain several minor phenolic
components with biological properties, such as the ability of modulating biomarkers involved in
pathways implicated in the development of atherosclerosis. Atherosclerosis may be considered an
inflammatory disease, characterized by the accumulation of macrophage-derived foam cells in the
vessel wall with the production of cytokines, chemokines, and growth factors, together with oxidative
stress. In this scenario, blood vessels are damaged, and their remodeling leads to blood flow restriction,
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responsible for heart and nervous system injury [8]. Among the phenolic compounds present in EVOO,
hydroxytyrosol (HT) was reported to counteract CVD, owing to a wide range of biological activities,
such as prevention of endothelial dysfunction and macrophages activation, in turn limiting low-density
lipoprotein (LDL) cholesterol oxidation, modulation of the blood lipid profile, reduction in platelet
aggregation and reduction in chronic inflammation [9–11]. This review describes the vast range of
known biological information about HT, focusing on its involvement in biological mechanisms of CVD.
It is the first attempt to collect the scientific literature on the effects of HT in both in vitro and in vivo
models and also in human clinical trials.
2. Methodology
A systematic literature search using PubMed and Web of Science databases was carried out
to summarize the biological activities of HT in cardiovascular diseases. The original articles
were individuated, employing the keywords: “hydroxytyrosol” AND “oxidative stress” OR
“anti-inflammatory” OR “bioavailability” OR “metabolism” OR “cardiovascular disease” OR “in vitro
study” OR “in vivo study”, including the period 2000–2020. This literature was beyond manual choice
in agreement to the importance to the focus. Literature from before the year 2000 was faithfully selected
and inserted when indispensable considering its importance to the reviewed topic. Studies on crude
olive extract or a mixture of olive polyphenols were excluded from this review.
3. Biochemical Properties of Hydroxytyrosol
HT is an amphipathic phenol with a phenyl-ethyl-alcohol structure (Figure 1) and is part of the
soluble fraction of extra virgin olive oil (EVOO).
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content of HT in olive oil is determined by the kind of olive tree, the location of the plantation, the oil 
quality, and the olive oil elaboration process [12]. 
HT effectiveness in vivo should be carefully evaluated considering the kinetics of absorption 
and metabolism of this compound after ingestion. Many studies have been performed in animals, 
and fewer in humans, in order to determine how adsorption, distribution, metabolism, and excretion 
of HT occurs. Similar to other phenolic compounds, HT is quickly absorbed in the small intestine and 
colon, mainly by passive transport, in a dose-dependent manner, with efficiency ranging from 75% 
up to 100% [15–17]. HT and all polyphenols are exposed to an extensive intestinal/hepatic metabolism 
in the human body, and their bioavailability is poor in plasma compared to their metabolites [17]. 
After ingestion, HT undergoes phase I of metabolism, being firstly hydrolyzed in enterocytes and 
subsequently, through phase II of metabolism, it is metabolized into glucuronide and methylated and 
sulphate bio-products [18,19]. After these processes, it is possible to detect 98% of HT in glucuronide 
form, in plasma and urine, and only 2% as its free form, when it is administered in olive oil [20].  
HT has a fast metabolism and its estimated plasma half-life in rats has been reported to be about 
2 min [21,22] and 8 min in human healthy volunteers [23]. A while ago, the maximum plasma 
concentration was reported to be around 7 min after intake in rats [24]. In spite of this, other authors 
have reported that the highest plasma concentrations of HT are reached between 30 min and 2 h after 
its oral administration, being practically undetectable after 4 h in rats [25]. In humans, the maximum 
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Due to the amphipathic character of HT, it can be found in olive mill wastewater, pomace, and olive
oil, on a free form, as acetate form or as a component of other compounds like oleacein, verbascoside,
tyrosol, and oleuropein [12,13]. HT is obtained from the hydrolysis of oleuropein which happens
naturally during the ripening of the olives, and with the over-time oil storage [14]. The content of HT
in olive oil is determined by the kind of olive tree, the location of the plantation, the oil quality, and the
olive oil elaboration process [12].
HT effectiveness in vivo should be carefully evaluated considering the kinetics of absorption
and metabolism of this compound after ingestion. Many studies have been performed in animals,
and fewer in humans, in order to determine how adsorption, distribution, metabolism, and excretion
of HT occurs. Similar to other phenolic compounds, HT is quickly absorbed in the small intestine and
colon, mainly by passive transport, in a dose-dependent manner, with efficiency ranging from 75% up
to 100% [15–17]. HT and all polyphenols are exposed to an extensive intestinal/hepatic metabolism
in the human body, and their bioavailability is poor in plasma compared to their metabolites [17].
After ingestion, HT undergoes phase I of metabolism, being firstly hydrolyzed in enterocytes and
subsequently, through phase II of metabolism, it is metabolized into glucuronide and methylated and
sulphate bio-products [18,19]. After these processes, it is possible to detect 98% of HT in glucuronide
form, in plasma and urine, and only 2% as its free form, when it is administered in olive oil [20].
HT has a fast metabolism and its estimated plasma half-life in rats has been reported to be
about 2 min [21,22] and 8 min in human healthy volunteers [23]. A while ago, the maximum plasma
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concentration was reported to be around 7 min after intake in rats [24]. In spite of this, other authors
have reported that the highest plasma concentrations of HT are reached between 30 min and 2 h after
its oral administration, being practically undetectable after 4 h in rats [25]. In humans, the maximum
concentration is detected after 13 min, decreasing till undetectable levels 1 h after administration [23].
In fact, once absorbed, HT quickly becomes part of plasmatic lipoproteins, acting as an antioxidant
and as a cardiovascular protector [26]. González-Santiago and coworkers, demonstrated in a group
of healthy volunteers, that about 70% of the total HT orally supplemented in aqueous solution,
was detected in plasma purified LDL, the concentration was higher after 10 min from the HT intake
and lower after 20 min, due to the fast HT elimination from the plasma [23].
In spite of the short plasma half-life, using Wistar rats as an in vivo model, HT and its metabolites
demonstrated the ability to good distribute in skeletal muscles, testis, heart, liver and also in the brain,
considering that HT is able to cross the blood–brain barrier, besides its metabolism ends in the liver and
in kidneys [15,21,27]. Thanks to this widespread distribution, HT exerts its health-beneficial properties
in all body tissues. In the kidney, HT is accumulated until its main excretion as conjugated catabolites,
still performing there a nephroprotective role due to its antioxidant properties [21,27,28]. The time
required for the complete elimination from the body, both for HT and its metabolites, is approximately
6 h in humans [18,29] and around 4 h in rats [25]. Adsorption and excretion processes for HT depend
not only on the in vivo model used but can also be influenced by the vehicle employed for the
administration [15,30].
4. Biological Effects of Hydroxytyrosol in Cellular In Vitro Models
Many studies have been carried out with different cellular models in order to observe the beneficial
effects of HT and to try to understand the underlying molecular antioxidant and anti-inflammatory
mechanisms and the anti-atherogenic action of the compound. All the biological activities of HT in
cellular in vitro models, directly related to atherosclerosis and CVD risk, are summarized in Table 1.
4.1. HT as Radical Species Scavenger: Protective Role against Oxidative Stress Contributing to Atherosclerosis
The induction and progression of CVD have been related to the disturbance of cellular redox
balance, characterized by increased levels of reactive oxygen species (ROS) and reactive nitrogen
species (RNS), such as superoxide anion (O2−), hydrogen peroxide (H2O2), hydroxyl radical (OH·) and
peroxynitrite (ONOO−) [31].
ROS are products of normal cell activity and participate in cellular signaling. However, high levels
of ROS have dangerous effects on cellular homeostasis and functions, resulting in oxidative stress
and endothelial dysfunction in vessel walls [32]. Therefore, lowering ROS production and restoring
cellular antioxidant defenses could prevent atherosclerosis risk. The superoxide dismutase 1 (SOD1)
enzyme catalyzes the transformation of two superoxide anions in a molecule of H2O2 and oxygen
(O2). After that, the detoxification initiated by SOD is completed by the catalase (CAT) enzyme,
which converts H2O2 to water and oxygen [31]. Glutathione peroxidase (GPx) is a selenium-containing
enzyme, which also catalyzes the degradation of H2O2, as well as organic peroxides to alcohol.
RNS are a family of nitrogen moieties associated with oxygen. They are generated when
nitric oxide (NO) interacts with reactive oxygen species, such as O2− and H2O2. Enzymatic NO
formation is catalyzed by NO synthase (NOS) enzymes (eNOS—endothelial, nNOS—neuronal,
and iNOS—inducible) through a series of redox reactions. The cardiovascular roles of NOSs have
been widely studied, and the findings supply significant insights into the importance of NOSs in CVD.
Overall, eNOS and nNOS exert protective effects, while iNOS has dual roles in the cardiovascular
system. NO is a key molecule involved in a variety of biological functions throughout the whole
body [33]. In the vasculature, NO (major part from eNOS, but nNOS is present around arterioles) plays
an important role in the protection against the onset and progression of CVD [34]. In the presence
of oxidative stress, NO reacts quickly with O2− producing the highly reactive intermediate OONO−,
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which causes severe damage in the endothelial tissue due to the uncoupling of the eNOS enzyme and
reduction in NO bioavailability [35], a hallmark of CVD.
HT has a strong antioxidant activity, due to its high capacity to eradicate both the intracellular
and extracellular production of ROS, being mainly effective with free radical molecules, such as O2−
and H2O2, acting as a metal chelator as well [36]. These properties are due to both the presence of
hydroxyl (OH) groups in ortho position, who have electron donating capacity, and to the HT ability to
bind phenoxyl radicals, forming stable hydrogen bonds (Figure 2) [37,38].
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Figure 2. Mechanism of free radical scavenging exerted by hydroxytyrosol (HT).
The antioxidant effect of HT does not depend only on the capacity of scavenging oxidant chemical
species, but also on the ability to stimulate the synthesis and activity of antioxidant enzymes SOD,
CAT, NOS, GPx and glutathione reductase (GR), also preserving the cellular high levels of reduced
glutathione (GSH) [39,40].
Diminished NO availability has been related to the development of atherosclerosis, and the
upregulation of eNOS activity could represent a strategy for the prevention of vascular complications.
In a study performed on human endothelial cells (EA.hy926) without inflammatory conditions,
no evidence was obtained after HT treatment (0.1–100 µM) on eNOS gene promoter transactivation,
eNOS enzyme activity and NO availability [41]. Nevertheless, in a recent paper using
hydroxytyrosol-nitric oxide (HT-NO), an experimental drug, in which HT was combined with
NO, demonstrated antioxidant and NO-releasing activities. HT-NO increased NO levels and decreased
oxidative stress activating deacetylase Sirtuin 1 (SIRT1) expression, in high glucose-stimulated human
umbilical vein endothelial cells (HUVECs). The ROS scavenger HT enhanced the effect of HT-NO on
eNOS phosphorylation [42]. HT was also investigated in ECV304 cells, a cellular model of endothelial
dysfunction in the type 2 diabetes condition. In this study, HT treatment (10 µM for 48 h) induced a
significant up-regulation of endothelin-1 (ET-1) and eNOS phosphorylation, as well as NO production,
being effective in the protection against endothelial dysfunction, induced by high glucose and free
fatty acids [43].
During oxidative stress, polyunsaturated fatty acids, present in the membranes of endothelial and
smooth muscle cells in blood vessels, are oxidatively damaged. Lipid peroxidation, especially referring
to LDL, has been reported to have an important role in the progression of atherosclerosis. Oxidized
LDL (oxLDL) is cytotoxic and chemotactic, and monocyte macrophages avidly remove oxLDL from
the interstitium, generating macrophage foam cells, the major cell type present within fatty streaks and
fibrous plaque [44].
The antioxidant effect of HT in counteracting LDL oxidation induced by copper sulphate is
not recent in the scientific literature, demonstrating the reduction in lipid peroxidation markers of
F2-isoprostanes, as well as a reduced decline in vitamin E throughout LDL oxidation in vitro [45,46].
Enriching LDL and HDL with tyrosol and HT (up to 25µM) led to a major resistance to
lipid peroxidation, also favoring the reverse cholesterol transport. Cholesterol efflux from THP-1
cells-derived macrophages was intensified, probably repressing the effect of Fe/Asc on the cell surface
receptors implicated in this process. Tyrosol and HT stimulated ATP binding cassette subfamily A
member 1 (ABCA1) protein expression in J774 macrophages, promoting the efflux of phospholipids and
cholesterol efflux to lipid-poor apoA-1, through a system involving the direct binding of apo-AI to the
ABCA1 transporter [47]. Another study by Atzeri et al. in 2016 showed the antioxidant role of HT in
neutralizing the pro-oxidant effect obtained treating Caco-2 human enterocyte-like cells with oxidized
cholesterol. Caco-2 cells, exposed to HT (5–25 µM), had significantly blocked malondialdehyde (MDA)
increase, inhibited ROS production, and induced glutathione peroxidase activity, whilst maintaining
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GSH levels and cell viability [48]. These results may be due to the antioxidant effect of the phenolic
compound HT, which may scavenge ROS and therefore prevent lipoprotein oxidation.
In vitro studies carried out on human neutrophils evidenced that the biophenol HT (up to 50 µM)
was able to remove N-formyl-methionyl-leucylphenylalanine (fMLP), phorbol myristate acetate (PMA),
and opsonized zymosan-induced injury, which is mediated by H2O2 in oxidative conditions [49].
Imbalance in mitochondrial functions, with production of higher levels of mitochondrial ROS
(mtROS), may also contribute to endothelial dysfunction and CVD. The endothelial protective effect of
HT occurs, also reducing mitochondrial superoxide production by improving mitochondrial function
and biogenesis. The HT pretreatment of PMA-activated endothelial cells reduced O2− production
and membrane lipid peroxidation as well as reduced mitochondrial membrane depolarization,
preventing mtROS overproduction. Moreover, HT increased mtDNA content and the master
regulator of biogenesis the Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α),
the transcription factor Nuclear respiratory factor-1 (NRF-1), and Mitochondrial transcription factor A
(TFAM) gene expression, resulting in an improved mitochondrial functionality [50].
In H9c2 cardiomyocytes with increased activity of xanthine/xanthine oxidase (X/XO),
which represent a risk factor for heart disease, HT treatment (0.1 and 10 µg/mL, for 24 h) induced
a reduction in intracellular ROS level and a modulation of stress-sensitive pathways across the
upregulation of defensive proteins, p44/42-MAPK and Hsp27 via c-Jun [51]. In porcine pulmonary
artery endothelial cells treated with H2O2, HT (10, 30 and 50 µM) prevented the intracellular
overproduction of ROS and induced AMP-activated protein kinase (AMPK) as well as forkhead
transcription factor 3a (FOXO3a), triggering the upregulation of the antioxidant enzyme CAT [52].
The protective effects of HT have also been reported on human erythrocytes, in which the HT
treatment reduced ROS production and increased GSH level, preventing haemolysis and morphological
alterations, induced by exposure to HgCl2 [53]. Another study highlighted that HT pre-treatment (10, 25
and 50µM) reduced erythrocyte phosphatidylserine (PS) exposure at the cell surface, and re-estabilished
ATP and GSH amount, indicating that HT could also take part in modulating the programmed death
in non-nucleated cells [54].
The HT antioxidant beneficial effects could also depend on the activation of signaling pathways
involved in the recognition of the free radicals’ presence. In fact, in human retinal pigment epithelial
cells, from the ARPE-19 cell line, 100 µM HT was demonstrated to modulate the expression of several
genes encoding for antioxidant response elements (ARE), such as DNA-repair proteins or phase II
detoxifying enzymes, inducing the nuclear factor-E2-related factor-2 (Nrf2) and JNK-p62/SQSTM1
pathway [55]. The HT induced synthesis and translocation of Nrf2, and the promotion of phase II
detoxifying enzymes, such as heme oxygenase 1 (HO-1), was also demonstrated by Zrelli et al. in 2011
and 2015, with particular interest in the atheroprotective effects of HT (50 µM) [56]. Zrelli and coworkers
showed the HT-mediated upregulation of HO-1 activity and increased cell proliferation and wound
closure on an in vitro model of a wound using cultured vascular endothelial cells (VECs). HT was
also effective in protecting VECs from oxidant-induced injury, stimulating the Nrf2 via PI3K/Akt and
ERK1/2 pathways [56,57].
4.2. Anti-Inflammatory Role of HT
Inflammation and the activity of the immune system are classically considered beneficial
and protective. In fact, inflammatory mediators, such as cytokines, chemokines, RNS, and ROS,
released directly by the immune system cells or by activated endothelial cells, can attract monocytes,
T- and B-lymphocytes, to the injured site, with the purpose of clearing infection and removing
debris while initiating tissue repair mechanisms [58,59]. The inflammatory response, generally quick
and self-limiting, is safe for the host, but may also have a detrimental effect if becoming a chronic
low-grade inflammation, as inevitably associated with older age, obesity and visceral adiposity,
triggering the prodromal stage of CVD, dementia, autoimmune diseases, and many more. In this
condition endothelial, smooth muscle, and peripheral blood cells are chronically exposed to high levels
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of potentially toxic molecules, proinflammatory cytokines, chemokines, eicosanoids (prostaglandins
and leukotrienes) and autoantibodies [60,61].
HT, tested in a concentration range from 12.5 to 50 µM, greatly reduced the
expression of iNOS, Cyclooxygenase-2 (COX-2), prostaglandin-endoperoxide synthase 2 (PTGS2),
chemokines (CCL5/RANTES, CXCL10/IP10, and CCL4/MIP1β), Interleukin-1α (IL-1α), and Matrix
metallopeptidase-9 (MMP-9) genes in the RAW264.7 macrophage cell line, previously stimulated with
the proinflammatory molecule LPS (lipopolysaccharides). The higher concentration of HT 50 µM
was more effective as an anti-inflammatory compound acting through Nuclear Factor-κB (NF-κB)
inhibition [62]. In human monocytic THP-1 cell lines, the HT molecular mechanism of action appeared
to be related to a crucial decrease in protein kinase C (PKC)-β1 and PKCα membrane translocation,
inhibiting proinflammatory cytokine production and the activation of iNOS [40]. Additionally,
in PMA-activated U937 human monocytes, 1–10 µmol/L of HT was able to reduce MMP-9 and COX-2
expression and activity through the inhibition of the nuclear translocation of NF-κβ and of PKCα and
PKCβ1 activation [63]. In a study from Takeda et al. (2014), it was shown that HT may also repress
NO production by a mechanism independent of the NF-κβ pathway [64]. Rosignoli et al. performed
an in vitro experiment on isolated human monocytes. Their data demonstrated that HT (100 µM)
significantly inhibited the production of superoxide anions (O2−), and reduced COX-2 expression and
PGE2 release [65]. Moreover, in J774 murine macrophages, HT also down-regulated proinflammatory
molecules, iNOS and COX-2, counteracting NF-κB, STAT-1α and IRF-1 activation, mediated through
LPS-induced ROS generation [39].
Data from these in vitro studies offer a molecular basis for clarifying the beneficial preventive
effects of HT on inflammatory signaling involved in atherosclerotic processes.
4.3. Modulation of Endothelial and Macrophage Activation in Protection from Atherosclerosis
Endothelial dysfunction is the prodromal stage of atherosclerosis, which exposes the individual
to an increased risk of CVD onset. E-selectin, P-selectin, Vascular Cell Adhesion Molecule-1 (VCAM-1),
Intercellular Adhesion Molecule-1 (ICAM-1), and the Monocyte Chemotactic Protein-1 (MCP-1)
molecules, can be considered as biomarkers of endothelial and immune cells dysfunction. In fact,
the leukocytes rolling on the vessels’ endothelial wall is mediated by E and P-selectin expression by
the activated endothelial monolayer that, subsequently expressing VCAM-1and ICAM-1, favors the
leukocyte adhesion. Leukocyte migration into the intima is then mediated by MCP-1 release.
The inhibition of endothelial activation by free HT was described in the HUVEC cell line, observing
that HT was able to reduce the LPS-stimulated expression of VCAM-1 at low micromolar concentrations.
The reduction in E-selectin, VCAM-1, and ICAM-1 expression was observed in HUVEC after HT
exposure at doses between 5 and 25 µM [66]. In a study performed on human endothelial cell
line EA.hy 926, HT treatment (0.5–2.5 µM) significantly reduced monocyte adhesion and ICAM-1
expression, induced by homocysteine [67]. In murine RAW264.7 macrophages cultured with 25 µM
HT, a significant reduction in MCP-1 was observed [62,68]
The reduction in MCP-1 and the increase in SOD1 antioxidant enzyme, were achieved in an
interesting paper using HUVEC treated with human serum, collected from recruited subjects, after their
intake of VOO with the high content of phenolic compounds. Carluccio et al. demonstrated that the
HT ability in counteracting endothelial inflammation and activation is mediated by the inhibition
of intracellular ROS and the NF-κB pathway, in the inflamed endothelium [69]. The treatment of
cultured HUVEC with serum obtained after the intake of the high-phenol VOO-based breakfast
in human healthy volunteers, significantly decreased p65, MCP-1, and CAT gene expression and
increased MT-CYB, SDHA and SOD1 gene expression levels [70]. Thus, decreasing inflammation and
improving the antioxidant profile in the vascular endothelium, olive oil phenolic compounds could
reduce atherosclerosis risk. Moreover, considering that, after the consumption of normal doses of VOO
(less than 50 g/day), the native form of HT is not detected in plasma, the potential health benefits of
VOO phenolic compounds could be either attributed to the biological activity of HT metabolites [71].
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Interestingly, cultured Human Aortic Endothelial Cells (HAEC) in the presence of Tumor Necrosis
Factor-α (TNFα) stimulation and synthetized HT metabolites, obtained in culture by intestinal Caco-2
cell line, resulted in the effective reduction in E-selectin, P-selectin, VCAM-1, and ICAM-1 [71].
4.4. Antithrombotic Effect
Among the processes involved in CVD and atherosclerosis, platelet aggregation must be considered.
HT showed anti-thrombotic activities, as it considerably diminished platelet aggregation both in vitro
and ex vivo, reducing thromboxane B2 levels, a chemically stable and inactive form of thromboxane A2,
NO and leukocyte inflammatory mediators [72,73]. In a study from Dell’Angi et al., human platelets
collected from healthy donors and stimulated with thrombin were used for an aggregation assay ex
vivo. Different olive oil polyphenols, including HT, showed the inhibition of platelet aggregation
through cAMP-phosphodiesterases inhibition as a mechanism of action [72].
Reyes and coworkers, in order to increase the lipophilicity of HT, synthetized HT alkyl ether
derivatives and tested the in vitro antiplatelet aggregation effect of the compound, compared to HT
tested in human whole blood. HT alkyl ether derivatives exerted greater antiplatelet aggregation and
anti-inflammatory effects than HT. This effect was explicated through a slight reduction in platelet
thromboxane synthesis, an enhancement in constitutive NO production and inhibition of iNOS as well
as COX-2 enzymes [74].
Table 1. Summary of relevant studies of HT in cellular in vitro models.
Study In Vitro Model Conditions HT Health Benefits
Salami et al.,
1995 [45] CuS04-treated LDL samples 10
−5 M HT ↓ F2-isoprostanes, ↑ Vit E
Visioli et al.,
1995 [46] CuS04-treated LDL samples HT range 10
−6–10−4 M ↑ Vit E, ↓ lipid peroxidation
Carluccio et al.,
2003 [66]
HUVECs and BAECs + LPS,
IL-1β, TNFα, or PMA 30 µM HT
↓ VCAM-1, ↓ ICAM-1, ↓ NF-kB,









HT range 0–25 µM ↑ ABCA1,
↑ apoA-I-mediated cholesterol efflux
Schmitt et al.,
2007 [41] EA.hy926 0.1–100 µM HT for 24 h
No effect on endothelial NO
bioavailability and eNOS activity
Carluccio et al.,
2007 [69] Hcy-stimulated HUVECs HT range 0.1–1 µM ↓ VCAM-1, ↓ ROS, ↓ NF-κB
Dell’Agli et al.,
2008 [72] Human platelets 10 µM HT ↓ cAMP-PDE, ↓ platelet aggregation
Zrelli et al.,
2011 [52] VECs + H2O2 10, 30, 50 µM HT for 24 h ↓ ROS, ↑ CAT, ↑ FOXO3a, ↑ pAMPK
Richard et al.,
2011 [62] LPS-stimulated RAW264.7 25 µM HT
↓ NO, ↓ PGE2, ↓ IL-1α, ↓ IL-1β, ↓ IL-6,
↓ IL-12, ↓ TNFα, ↓ CXCL10/IP-10,
↓ CCL2/MCP-1, ↓ iNOS, ↓MMP-9
Zou et al.,
2012 [55] VECs + H2O2 50 µM HT
↑ pAkt, ↑ p-p38, ↑ pErK,
↑ Nrf2, ↑ HO-1, ↓ ROS
Scoditti et al.,
2012 [76] HUVEC + PMA 10 µM HT ↓MMP-9, ↓ COX-2, ↓ PGE2, ↓ NF-kB
Rosignoli et al.,
2013 [65] PMA-activated PBMC 100 µM HT ↓ O2




U937 HT range 1–10 µM
↓MMP-9, ↓ COX-2, ↓ PGE2,




peritoneal macrophages 12.5 µg/mL HT ↓ iNOS, ↓ NO
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Table 1. Cont.
Study In Vitro Model Conditions HT Health Benefits
Storniolo et al.,
2014 [43] HG-stimulated ECV304 10 µM HT for 48 h ↓ ROS, ↑ ET-1, ↑ p-eNOS, ↑ NO
Scoditti et al.,
2015 [75] SGBS cells + TNFα HT range 0.1–20 µM ↓ pJNK, ↑ adiponectin, ↑ PPARγ
Catalán, et al.,
2015 [71] TNF-α-stimulated HAEC 1, 2, 5, 10 µM HT for 24 h
↓ E-selectin, ↓ P-selectin, ↓ VCAM-1,
↓ ICAM-1, ↓MCP-1
Ozbek et al.,
2015 [51] H9c2 + O2
− HT range 0.1-10 µg/mL
for 24 h
↓ ROS, ↓ pMAPKAPK-2,
↓ pErk1/2, ↑ Hsp27, ↓ c-CASP3
Zrelli et al.,
2015 [57] VECs HT range 10-100 µM ↑ PI3K/Akt, ↑ pErK, ↑ Nrf2, ↑ HO-1
Tagliaferro et al.,
2015 [53]
Hg induced hemolysis of
human RBC HT range 10-80 µM ↓ ROS, ↑ GSH
Officioso et al.,
2016 [54]
Hg induced hemolysis of








and HMEC-1 HT range 1–30 µM
↓TNFα, ↓IL-1β, ↓VCAM-1,
↓ ICAM-1, ↓mtROS,




926 HT range 0.5–2.5 µM ↓ ICAM-1
Wang et al.,
2019 [42] HG-stimulated HUVECs
25, 50, 100 µM HT-NO
for 48 h ↑ p-eNOS, ↑ NO, ↓ ROS, ↑ SIRT-1
↓: decrease, ↑: increase, VCAM-1: vascular cell adhesion molecule- 1, ICAM-1: intercellular adhesion
molecule-1, NF-κB: Nuclear Factor kappa-light-chain-enhancer of activated B cells, AP-1: Activator protein
1, ABCA1: ATP-binding cassette transporter A1, NO: nitric oxide, eNOS: endothelial Nitric Oxide Sinthase,
ROS: Reactive Oxygen Species, CAT: catalase enzyme, FOXO3a: Forkhead box O3, AMPK: AMP-activated protein
chinasi, PGE2: Prostaglandin E2, TNF: Tumor Necrosis Factor, iNOS: inducible Nitric Oxide Sinthase, CXCL10/IP-10:
IFN-γ-inducible protein 10, CCL2/MCP1: chemokine (C-C motif) ligand 2, MMP-9: matrix metalloproteinase
9, Akt: serine/threonine-protein kinases, ERK: extracellular signal-regulated kinases, Nrf2: nuclear factor
erythroid 2-related factor 2, HO-1: Heme oxygenase 1, COX: Cyclooxygenase, O2−: superoxide anion,
HG: High Glucose, ET-1: endothelin-1, GPx: Glutathione Peroxidase, fMLP: bacterial chemotactic peptide
n-formyl-methionine-leucine-phenylalanine, IL: interleukin, mtROS: mitochondrial ROS, MDA: Malondialdehyde,
MnSOD: manganese superoxide dismutase, MAPKAPK-2: Mitogen-activated protein kinase-activated protein kinase
2, Hsp27: Heat shock protein 27, c-CASP3: cleaved caspase-3, PI3K: Phosphoinositide 3-kinases, Hcy: Homocysteine,
PDE: Cyclic nucleotide phosphodiesterases, JNK: c-Jun N-terminal kinase, PPAR: peroxisome proliferator-activated
receptors, SIRT-1: sirtuin 1.
4.5. Antiadipogenic Role
Local and systemic chronic low-grade inflammation with increased oxidative stress, are typically
present in obesity and play a key role in both CVD and type 2 diabetes mellitus. The major amount of
adipose tissue in obesity is characterized by an aberrant production of pro-inflammatory cytokines,
among which TNFα, derived from both adipocytes and infiltrating macrophages, and adipose tissue
specific adipokines [8,75]. Scoditti et al. demonstrated the stimulatory effects of HT on adiponectin,
after the TNFα-induced downregulation of this adipokine expression, in cultured adipocytes. Indeed,
adiponectin, is an adipocyte-derived insulin-sensitizing and anti-inflammatory hormone, that is
reduced in obesity through mechanisms involving chronic inflammation and oxidative stress, as well
as with anti-diabetic, anti-inflammatory, and anti-atherogenic properties [75,76].
Molecular studies have also shown that HT might control the expression of adipogenesis-associated
genes. HT-treated primary human omental pre-adipocytes significantly increased the expression
of GATA2, GATA3, WNT3A, SFRP5, HES1, and SIRT1 genes involved in adipogenesis suppression.
Genes involved in promoting adipogenesis, such as LEP, FGF1, CCND1, and SREBF1, a transcription
factor necessary for lipogenesis, were significantly down-regulated. Moreover, HT treatment was
able to reduce triglyceride accumulation in adipocytes, suggesting a lipolytic and apoptotic activity
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in primary human visceral pre-adipocytes during differentiation, regulating the expression of genes
involved in adipogenesis and fat storage pathways [77]. These achievements demonstrate that HT can
have a protective role against fat accumulation and obesity and, therefore, can be useful in preventing
diseases caused by these factors.
5. Health Beneficial Effects of Hydroxytyrosol Demonstrated in Animal In Vivo Models
To better elucidate the effects and the molecular mechanisms of the HT protection against LDL
oxidation, inflammatory response and macrophages and endothelial activation, as well as obesity,
hyperlipidemia and cancer, in vivo animal models were largely used. The HT administration to
in vivo animal models allowed the investigation of the potential healing role of the compound in a
more complex picture, mimicking the pathological condition. A summary of relevant studies on HT
supplementation in animal models is reported in Table 2.
5.1. Protection of Low-Density Lipoprotein (LDL) from Oxidation
Lipid peroxidation, especially referred to oxidative modified LDL, has been reported to have a key
role in atherosclerotic plaque formation. A minor susceptibility to lipid peroxidation and particularly to
LDL oxidation was found significant in a rabbit model fed with an olive oil rich diet [78]. Using Wistar
rats fed a cholesterol-rich diet for 16 weeks demonstrated the significant reduction in lipid peroxidation
in liver, heart, kidney, and aorta, specifically due to HT orally administered to rats, compared with those
animals fed only the cholesterol-rich diet. This antioxidant activity could be explained with increased
CAT and SOD enzymatic activities observed in the liver of this hypercholesterolemic rat model [79,80].
HT supplementation was also effective in decreasing the oxidation levels of lipids and proteins in both
liver and muscle tissue. This effect was obtained decreasing muscle mitochondrial carbonyl protein
levels and thus improving mitochondrial complex activities in C57BL/6J mice model, in which obesity
and oxidative stress was induced through high-fat-diet [81]. HT also improved the cardiac disturbances
enhanced by doxorubicin in rats, by significantly reducing the percentage of altered mitochondria and
oxidative damage and improving the mitochondrial electron transport chain [22]. The antioxidant role
of HT was also supported by its protective effect against the NO-mediated vasorelaxation after the
induction of oxidative stress in rat aorta [82]. Excised rat aorta pre-incubation with HT, before treatment
with cumene hydroperoxide, an oxidative injury inducer through OH· generation, preserved the
vasodilation mediated by NO, recovering the aortic vascular tone ex vivo. This effect was attributed
to high scavenging activity of HT due to the presence of a catechol moiety in their structure [82].
These results suggested that HT could be a natural antioxidant with a possible role in the prevention of
atherosclerotic lesions and cardiovascular events.
Table 2. Summary of relevant studies on HT supplementation in animal models and obtained effects.




diet induced for 1 month
4 mg/kg HT
for 1 month








+ 10 mg/kg OMW
↓ TC, ↓ LDL, ↑ HDL, ↓
TBARS in liver, heart, kidney,
and aorta,













3 mg/kg/day HT and
triacetylated HT
↓ TC, ↓ TG, ↓ LDL, ↓ TBARS
in liver, heart, kidney, and
aorta, ↑ HDL,
↑ CAT, ↑ SOD1
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Table 2. Cont.
Study In Vivo Model Conditions HT Health Benefits
González-Correa et al.,
2008 [85] Wistar rats
1, 5, 10, 20, 50, 100
mg/kg/day HT, HT-ac or




↓ prostacyclin, ↑ NO
Cao et al.,
2014 [81]
C57BL/6J mice high fat
diet fed for 17 w
10 and 50 mg/kg/day HT
for 17 w
↓ body and organs weight, ↓
HOMA-IR index, ↓ leptin, ↓
IL-6, ↓ CRP,
↓ TG, ↓ HDL, ↓ LDL,
↓ SREBP-1c, ↓ FAS, ↑ SOD1
db/db metabolic
syndrome mice
10 mg/kg/day HT or
225mg/kg/day
metformin for 8 w
↓ TG, ↓ TC, ↓ HDL, ↓ LDL,





25 mg/Kg/day HT, HT-ac,
HT-et for 8 w
↓ TC, ↓ LDL, ↓ glucose,






streptozotocin-induced 77 mg/kg/day HT for 4 w
↓ blood glucose, ↓MDA,
↑ NO, ↑ SOD1
↓: decrease, ↑: increase, TC: Total cholesterol, TG: Triglycerides, LDL: low density lipoprotein, HDL: high density
lipoprotein, w: weeks, CAT: catalase enzyme, OMW: phenolic-rich extract of olive mill wastewaters,
SOD1: superoxide dismutase enzyme 1, MDA: Malondialdehyde, NO: nitric oxide, HT-ac: acetate, HT-et: ether,
TNFα: Tumor necrosis index, CRP: C reactive protein, SREBP-1c: sterol regulatory element-binding transcription
factor 1c, FAS: fatty acid synthase, TBARS: thiobarbituric acid-reactive substances, ORAC: oxygen radical
scavenging capacity.
5.2. Improvement of Blood Lipid Profile
Plasmatic hyperlipidemia is the result of changes in lipid metabolism in the body and is a
major cause of atherosclerosis. Hypercholesterolemia, or more specifically increased plasma levels of
LDL cholesterol, is an important risk factor for the development and progression of atherosclerosis.
The administration of HT (3 mg/kg of body weight) decreased significantly the serum levels of total
cholesterol (TC), triglycerides (TG), and LDL and increased the serum level of high-density lipoprotein
(HDL) in a diet-induced hypercholesterolemic rat model [79]. These results are in accordance with
a previous study, in which lower dose of HT (2.5 mg/kg of body weight) significantly reduced
the serum levels of TC and LDL, while increasing HDL, in the same rat model [80]. Recently,
the comparative evaluation between HT, HT-acetate, and HT-ether supplementation in diet-induced
hypercholesterolemic Wistar rats, showed improved cholesterol, glucose, insulin, and leptin levels
together with an increased antioxidant capacity status, with HT-acetate being the most effective
compound [83].
In a rabbit model of atherosclerosis, induced with 1-month of a high-fat diet containing 2.5 times
more saturated fat and 1.3% more cholesterol than a standard diet, supplementation with 4 mg/kg
of purified HT improved the blood lipid profile, the antioxidant status also reduced the size of
the atherosclerotic lesions histologically evaluated [84]. Within liver and skeletal muscle tissues,
HT effectiveness was demonstrated to reduce lipid deposits due to a high-fat-diet through the
inhibition of the SREBP-1c/FAS pathway. These achievements were obtained after 17 weeks of HT
supplementation in C57BL/6J mice, in which obesity and hyperlipidemia was induced through a
high-fat-diet [81]. These results suggested that HT administration might improve the blood lipid
profile and obesity, reducing the risk of atherosclerotic lesions.
5.3. Hypoglycemic Ability
Cao and coworkers also potentially linked the olive oil component HT to diabetes and metabolic
disease treatment. They demonstrated that HT could prevent obesity, hyperglycemia, and insulin
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resistance, after 17 weeks of supplementation in db/db mice, a model of metabolic syndrome (MetS)
with obesity and type 2 diabetes induced by the nonfunctional leptin pathway [81]. In this model,
10 mg/kg/day of HT significantly decreased fasting glucose, similar to 225 mg/kg/day metformin.
Moreover, HT was also able to decrease fasting serum levels of TC, HDL, and LDL, at which metformin
failed [81]. In streptozotocin-induced diabetic mice, 77 mg/Kg of HT significantly lowered blood
glucose, at 4 weeks [42]. HT health benefits could not be limited to decreases in oxidative stress,
suggesting a potential pharmaceutical or clinical use of HT in MetS treatment.
5.4. Anti-Inflammatory Activity
The excessive deposition of adipose tissue with adipocytes dysregulated the production of
pro-inflammatory cytokines, such as TNFα, IL-1β, IL-6, leptin, and adiponectin, which might participate
in the development of insulin resistance, endothelial dysfunction and atherosclerosis in obese patients
and in the associated MetS [8]. Serum IL-6 and C-reactive protein (CRP) levels were significantly
increased in high fat diet-induced obese mice, demonstrating an increased inflammation in obesity
condition. Both low and high doses of HT (10 mg/kg/day and 50 mg/kg/day, respectively) efficiently
decreased the elevated IL-6 level, and high-dose HT treatment diminished the CRP level by 22.4% [81].
Diet supplementation with HT, HT-acetate, and HT-ether in Wistar rats fed with cholesterol-rich diets,
showed anti-inflammatory effects, decreasing the plasma level of TNFα and IL-1β pro-inflammatory
cytokines. Moreover a significant decreased in MCP-1 and IL-1β below the control levels (group of
rats fed standard rodent diet without HT supplementation) was detected in the visceral adipose tissue
from the retroperitoneal area of this rat model, supplemented with HT [83].
5.5. Antithrombotic Effect
Platelet aggregation is one of the main events occurring in arterial and venous thrombosis and HT
inhibitor effect on platelets aggregation could be potentially useful in new therapeutical approaches to
CVD. González-Correa et al. compared the effect of orally administered HT and its main metabolite
HT-acetate, with that of acetylsalicylic acid, chosen because of its wide use in ischemic CVD prevention.
All three compounds studied (48.25 mg/kg per day for HT, 16.05 mg/kg per day for HT-acetate,
compared to 2.42 mg/kg per day of acetylsalicylic acid) inhibited collagen-induced platelet aggregation
in whole blood and in a dose-dependent way, in Wistar rats [85]. Moreover, the platelet synthesis of
thromboxane B2 was inhibited by up to 30% by HT and 37% by HT-acetate.
6. Health Beneficial Effects Demonstrated Through Clinical Trials in Humans
The availability of clinical studies in humans, considering the effects of VOO and EVOO is wide
and the PREDIMED study (Prevención con Dieta Mediterránea), conducted in Spain from 2003 to
2011, made a big effort to assess the effects of the Med diet on the prevention of atherosclerosis and
CVD [86–88], and MetS [89,90]. Although the incidence of cardiovascular events was lower among
patients who followed a Med diet regimen integrated with EVOO, no further investigations were
conducted in the PREDIMED study and in its subsequent sub-studies, on the specific effect of the
olive oil polyphenols, on CVD risk. The NUTRAOLEUM study evaluated the effect of VOO enriched
with phenolic compounds and triterpenes, on MetS and on biomarkers of endothelial function in
healthy adults. The daily intake of VOO high in phenolic compounds ameliorated plasma HDL
cholesterol levels, one of the features of MetS. In addition, VOO with phenolic compounds improved
the systemic endothelin-1 levels in vivo and ex vivo [91–93]. Studies about purified polyphenols
and HT supplementation in humans are still limited. However, in 2011, the European Food Safety
Authority (EFSA) endorsed the health claim on HT consumption for the protection of blood lipids
from the oxidative damage [94].
Table 3 elaborates on the available scientific literature about HT supplementation in human
clinical trials.
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6.1. Protection of Low-Density Lipoprotein (LDL) from Oxidation
Well-designed studies contributed to the claim of HT as antioxidant compound for circulating LDL
by EFSA; among these, we reported on the multicenter scientific work of Covas et al. in 2006 [95]. In the
study, 200 healthy male volunteers were randomly assigned to three sequences of daily administration
of 25 mL of three different olive oils containing 2.7 mg, 164 mg, or 366 mg per kg of oil of phenolic
compounds. The intervention periods was 3 weeks. A linear decrease in oxLDL for low-, medium-,
and high-polyphenol olive oil with more than a 3-fold decrease for higher concentrations of polyphenols,
was observed [95]. Considering the same quantity of oral intake of phenolic compounds in olive oil
(366 mg/kg, 164 mg/kg, and 2.7 mg/kg), Covas and coworkers also observed a modulation in the LDL
phenolic content and a reduced postprandial oxidative stress, in 12 healthy male volunteers. The higher
the phenolic content of the olive oil administered, the lower the resulting LDL oxidation level [96].
Table 3. Summary of relevant studies on HT supplementation in humans and its reported effects.






0.2 µmol g−1 and 45.4 µmol g−1
HT, single dose
↓ IL-1β, ↓ IL-6, ↓ PTGS2,
↓NF-κB/MAPK/AP-1 pathway,
↓ chemokines
de Bock et al.,
2013 [99]
No. 46 overweight men,
age range 35–55
9.7 mg/day HT and





No. 28 healthy subjects,
age range 18–65 15 mg/day HT for 3 w
↑ SOD1, ↑ thiol group, ↑ TSA,
↓MDA, ↓ nitrite, ↓ nitrate,





No. 84 healthy subjects,
age range 45–65
9.9 mg/day HT and 195 mg/day
punicalagin, for 20 w
↓ ox-LDL,
↓ SYS and DIA blood pressure
↓: decrease, ↑: increase, PTGS2: Prostaglandin-Endoperoxide Synthase 2, MAPK; mitogen-activated protein
kinase, w: weeks, SOD1: superoxide dismutase enzyme 1, AP-1: Activator protein 1, TSA: total antioxidant status,
MDA: malondialdehyde, LDL: low-density lipoproteins, SYS: Systolic, DIA: Diastolic.
Interesting results were also obtained in 40 male subjects with stable coronary heart disease, in a
placebo controlled, crossover, randomized trial [37]. Using EVOO and refined olive oil with polyphenol
contents 161 mg and 14.7 mg per kg of oil, respectively, significant lower plasma levels of oxLDL,
together with higher activities of glutathione peroxidase, were observed after EVOO intervention.
Additionally, the systolic blood pressure significantly decreased after the intake of EVOO, in these
hypertensive patients [37].
A more recent randomized, double-blinded, placebo-controlled, crossover trial was performed
for 20 weeks by Quirós-Fernández et al. in 2019, demonstrating the effectiveness of 9.9 mg HT daily
supplementation, together with 195 mg of punicalagin (from pomegranates), on early atherosclerosis
markers. In 84 recruited subjects, aged between 45 and 65 years, the oral supplementation of compounds
increased endothelial function in flow-mediated dilatation, reduced oxLDL, and also decreased the
systolic and diastolic blood pressure, compared to placebo [97]. The modulation of these early
atherosclerosis markers was especially effective in individuals in whom these parameters were altered.
A significant decrease in nitrite, nitrate, and MDA, as well as an increase in thiol groups, used as
oxidative stress biomarkers, were obtained after 15 mg/day HT supplementation, in healthy volunteers,
recruited in a clinical trial from Colica and coworkers in 2017 [98]. A significant upregulation of
SOD1 gene expression was also detected, without, however, observing a reduction in oxLDL levels.
These obtained results were positively correlated with the significant increase in HT bioavailability [98].
6.2. Modulation of Blood Lipid Profile
The multicenter scientific work of Covas et al. in 2006 also demonstrated a linear increase in
HDL cholesterol levels for low-, medium-, and high-polyphenol olive oil, after 3 weeks administration
in 200 healthy males [95]. TC–HDL ratio decreased linearly with the phenolic content of the olive
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oil. Triglyceride levels decreased by an average of 0.05 mmol/L for all types of administered olive
oils [95]. No significant changes were observed in healthy volunteers, after HT supplementation in
oral capsules (15 mg/day) for a 3 week period, observing peripheral triglycerides, TC, and HDL levels.
However, a significant reduction in body weight and suprailiac skinfold were both reported after HT
supplementation with respect to baseline [98].
6.3. Increased Insulin Sensitivity
Very limited data are available on the possible effects of HT and olive oil polyphenols on glucose
homeostasis in humans. A randomized, double-blinded, placebo-controlled, crossover trial was well
designed in New Zealand, supplying 46 middle-aged overweight men, with capsules containing
51.1 mg oleuropein and 9.7 mg HT, or placebo, per day for 12 weeks [99]. The primary outcome was
insulin sensitivity, which had improved by 15% together with the increased pancreatic β-cell secretory
capacity, in recruited overweight middle-aged men, possibly reducing the risk of developing the
MetS [99].
6.4. Anti-Inflammatory Activity
Recently, a sub study of 1139 CVD high-risk participants was carried out within the PREDIMED
(Prevención con Dieta Mediterránea) trial, demonstrating a significant inverse correlation between total
urinary polyphenol excretion (TPE) and plasma concentration of VCAM-1, ICAM-1 and inflammatory
biomarkers IL-1β, TNFα, and MCP-1, suggesting a dose-dependent anti-inflammatory effect of
polyphenols. Instead, a positive correlation was found between plasma HDL cholesterol and urinary
TPE levels [88]. However, in the scientific study, specific considerations about the HT compound were
not found. Camargo et al. observed that VOO in vivo (HT content 0.2 µmol g−1 and 45.4 µmol g−1,
respectively in low-phenol and high-phenol olive oil) was able to downregulate the expression of
several genes related to inflammation pathways in patients with MetS, during the postprandial period.
A decreased expression of IL-6, IL-1β, PTGS2, and diverse chemokines, as compared to low-phenol olive
oil intake, was detected. Proinflammatory stimuli, such as IL-6, IL-1β and TNFα cytokines, up-regulate
PTGS2 expression and thus COX-2 and prostaglandin synthesis, indeed chronically influencing the
inflammatory condition [100]. The authors described these anti-inflammatory effects as a consequence
of phenol interaction with the NF-κB/MAPK/AP-1 signaling pathways. Thus, the anti-inflammatory
effect of HT contributes to the atheroprotective properties of olive oil, suppressing the iNOS/NO and
the COX/PGE2 pathways, leading to a minor atherosclerotic plaque instability and risk reduction in
acute cardiovascular events [101].
6.5. Antithrombotic Effect
Ruano and coworkers evaluated the effects of olive oil phenols on endothelial reactivity,
also considering that endothelial-dependent vasodilatation and oxidative stress are impaired during the
postprandial phase, favoring a thrombogenic state. In 21 hypercholesterolemic middle-aged volunteers,
the same olive oil was administered during breakfast meals, but with a different content of its natural
phenolic compounds, 400 ppm or 80 ppm. Polyphenol-rich oil was associated with a significant
increase in NO levels and improving endothelium functions and microvascular vasodilatation 2 h after
the breakfast intake [102]. Moreover, 2 h after the high-phenol meal, concentrations of activated factor
VII (FVIIa) increased less, and plasmatic plasminogen activator inhibitor-1 (PAI-1) activity decreased
more than after the low-phenol meal. The VOO with the higher content of phenolic compounds
modulated the postprandial hemostatic profile, making it less thrombogenic. However, in both studies,
the phenolic composition of the olive oils used was not properly characterized [103].
7. Conclusions
In this review, we have reported on the pleiotropic effects of HT in CVD prevention, and we
have strengthened the relationship between inflammation, obesity, oxidative stress, and diet,
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providing evidence of healthy effects derived from VOO consumption and HT. The scientific data
available to date are encouraging, and the use of HT also in the form of a dietary supplement seems
promising as an adjuvant of drug therapy. However, it would be necessary to evaluate how longer HT
beneficial effects are maintained after feeding and to better characterize the effects carried out by the
several olive oil phenolic compounds, in order to understand if they act synergistically. Moreover,
even if 5 mg/die is the minimum HT dose recommended by EFSA, the HT doses used in the wider
literature here reported would suggest the need for personalized HT supplementation, in order to
exert its health benefits in CVD prevention. Thus, further human clinical trials are needed, with a
larger population over a longer period, in order to increase knowledge about therapeutic mechanisms
and ensure HT efficacy.
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